Adeona Pharmaceuticals receives $409K grant for MS drug development

Adeona Pharmaceuticals recently received a $409,426 grant from the National Multiple Sclerosis Society to further the development of its drug Trimesta, a move that has capped a year of growth for the Ann Arbor-based staff and business.”It’s a vote of confidence in our work on Trimesta,” says Dr. James Kuo, CEO of Adeona Pharmaceuticals. He adds that the National Multiple Sclerosis Society is the pre-eminent non-profit geared toward fighting multiple sclerosis. Adeona Pharmaceuticals has already received a $5 million grant from the National Multiple Sclerosis Society, along with another $1.1 million in funds for the clinical trials of Trimesta. So far the clinical trial for the oral drug is 85 percent enrolled and is expected to fill completely later this year. A handful of executives have been added to the staff of about a dozen people over the last year. They include a new vice president of finance, vice president of research & development, and a director of communications.  The 8-year-old company specializes in drugs that address problems in the central nervous system, such as multiple sclerosis and Alzheimer’s. It commonly licenses these drugs at the clinical stage to large pharmaceutical companies. Source: Dr. James Kuo, CEO of Adeona PharmaceuticalsWriter: Jon ZemkeRead more about Metro Detroit’s growing entrepreneurial ecosystem at SEMichiganStartup.com.